Pivotal Phase 3 Trial Reveals Investigational Drug Daraxonrasib Nearly Doubles Survival in Advanced Pancreatic Cancer

An international Phase 3 clinical trial has demonstrated that the investigational targeted therapy daraxonrasib nearly doubles the median overall survival for patients with metastatic pancreatic cancer compared to conventional second-line chemotherapy. The landmark findings from the RASolute 302 trial, presented at the American Society of Clinical Oncology annual meeting in Chicago and published in the New England Journal of Medicine, showed a 60% reduction in the risk of death among participants. Observers in the oncology community labeled the results unprecedented for an intractable disease that has long resisted targeted molecular therapies, even as the drug awaits formal regulatory approval from the U.S. Food and Drug Administration.

CHICAGO — Clinical trial results unveiled at the American Society of Clinical Oncology (ASCO) annual congress on Sunday, May 31, 2026, have signaled a potential paradigm shift in the treatment of metastatic pancreatic cancer, one of the most lethal malignancies in modern oncology. The data from the global, randomized Phase 3 RASolute 302 clinical trial showed that an oral, targeted small molecule named daraxonrasib significantly outperformed standard-of-care chemotherapy, nearly doubling the median survival duration for patients who had already failed initial frontline treatments.

The trial, which evaluated 500 patients across international clinical sites, demonstrated that those receiving daraxonrasib achieved a median overall survival of 13.2 months, compared to just 6.7 months for patients assigned to the investigator’s choice of cytotoxic chemotherapy. Furthermore, the targeted drug reduced the absolute risk of death by 60% relative to the control arm, establishing a statistically airtight benefit that drew a rare standing ovation from the assembled physicians during the plenary session in Chicago.

Though the medication has not yet received formal approval from the U.S. Food and Drug Administration (FDA), the simultaneous publication of its underlying data in the New England Journal of Medicine has accelerated discussions between federal regulators and its developer, Revolution Medicines, regarding an expedited approval pathway.

Unlocking the Undruggable: The Science of RAS Inhibition

To contextualize the clinical value of daraxonrasib, it is necessary to understand the unique genetic landscape of pancreatic ductal adenocarcinoma (PDAC). For more than four decades, oncologists and molecular biologists have recognized that mutations in the RAS family of oncogenes—specifically the KRAS variant—drive more than 90% of all pancreatic tumors. When mutated, these proteins act as defective cellular switches, stuck permanently in an “on” signaling configuration that commands cells to divide uncontrollably and resist natural cell death.

Despite its ubiquity, RAS was historically written off by the pharmaceutical industry as “undruggable.” The protein’s smooth, spherical physical structure lacked the deep, accessible binding pockets typically targeted by traditional small-molecule inhibitors. Early-generation KRAS inhibitors, such as sotorasib and adagarasib, managed to break through this barrier but were highly constrained; they could only bind to the protein when it shifted into its rare, inactive “off” state, and their efficacy was strictly limited to a minor sub-variant known as the KRAS G12C mutation.

Daraxonrasib bypasses these historical limits through a unique biochemical mechanism. Classified as a multi-selective RAS(ON) inhibitor, the drug acts as a “molecular glue.” Once ingested, it binds to an abundant intracellular protein called cyclophilin A, forming a complex that sterically blocks the active, signaling state of both mutant and wild-type RAS proteins. This means the drug can effectively neutralize up to 90% of pancreatic tumors driven by various KRAS mutations—including the highly prevalent G12D, G12V, and G12R variants—making it a broadly applicable targeted weapon rather than a niche therapy.

A Deeper Dive into the Trial Metrics and Survival Data

The RASolute 302 trial was meticulously structured to challenge the prevailing standard of care. Investigators enrolled 500 adult patients with confirmed metastatic pancreatic cancer whose disease had progressed after receiving one prior line of systemic chemotherapy (such as FOLFIRINOX or gemcitabine plus nab-paclitaxel). The cohort maintained a median age of 66, with an even split between male and female participants, all displaying a baseline ECOG Performance Status score of 0 or 1, indicating they were still fully capable of self-care and daily activity.

The trial participants were randomized on a strict 1:1 ratio. The experimental arm consisted of 248 patients who received a daily oral dose of 300 mg of daraxonrasib, completely eliminating the need for regular intravenous infusions. The control arm comprised 252 patients who received an investigator’s choice of standard cytotoxic chemotherapy cocktails, including FOLFOX, modified FOLFIRINOX, or nanoliposomal irinotecan combinations.

At a median follow-up mark of 8.5 months, the final independent central review yielded the following data points:

Crucially, sub-group analyses verified that the survival benefit remained entirely consistent regardless of the patient’s specific RAS mutation status. Even patients classified as RAS wild-type—meaning their tumors lacked a traditional RAS mutation but relied on standard RAS pathways for survival—experienced meaningful therapeutic responses, widening the drug’s eventual target demographic.

Clinical Perspectives and Patient Experiences

“I think many of us would consider this a big win,” said Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research and Gastrointestinal Cancer Center at the Dana-Farber Cancer Institute, in a national television broadcast on Monday morning. Reviewing the historical context of the disease, Wolpin added: “The trial is trying to help people live as long as they can and actually live better with less side effects, less symptoms from the cancer, and that is a very big deal.”

The real-world implications of these data are illustrated by the experiences of patients enrolled within the experimental arm. Jim, a trial participant who spoke on condition of using his first name to protect family privacy, recalled the profound emotional weight of his initial stage-IV diagnosis. “It’s news that can set you back or it can push you forward,” he noted. After commencing his daily oral regimen of daraxonrasib, follow-up CT scans revealed that a secondary tumor resting in his liver had shrunk by 50%. The dramatic reduction in tumor burden has allowed his household to move past short-term crisis management. “We are now back in the mode of rescheduling trips,” Jim shared.

Carla Walker, another advanced pancreatic cancer patient enrolled in the protocol, reported a 40% mass reduction in her secondary tumors while the primary mass in her pancreas has remained entirely stable, showing zero signs of active progression. For Walker, the clinical extension of time directly translates into personal milestones. “I would love, love to make it to their graduation from high school, and that’s like a long-term goal, and that’s what I look forward to,” Walker stated, referencing her grandsons. “I’m going to be there, no matter what.”

Safety Profiles and Quality-of-Life Tracking

Beyond raw survival metrics, the trial recorded a substantial divergence in how the two distinct treatments impacted the daily physiological well-being of the patients. Cytotoxic chemotherapy works by non-selectively destroying rapidly dividing cells throughout the body, routinely causing severe bone marrow suppression, debilitating fatigue, chronic hair loss, and intense nausea. In contrast, as a targeted inhibitor, daraxonrasib confines its primary chemical activity to cells over-expressing RAS pathways.

According to the trial data, Grade 3 or higher treatment-related adverse events occurred in 43.6% of the daraxonrasib cohort, compared to a significantly higher 57.5% within the chemotherapy arm. This variance in tolerability had a direct impact on trial retention: only 1.2% of patients receiving daraxonrasib were forced to permanently discontinue their treatment due to side effects, whereas 11.2% of the chemotherapy patients abandoned their assigned regimens due to toxicity.

However, researchers noted that daraxonrasib is not without its own distinct side-effect profile. The most common adverse reactions reported in at least 10% of patients included skin rash, diarrhea, nausea, fatigue, and stomatitis (painful inflammation and ulceration of the mucous membranes inside the mouth). Clinical trial nurses emphasized that the rash can be particularly severe, sometimes presenting as highly inflamed, sore eruptions across the face and upper torso that occasionally bleed.

“The rash can be tough, there’s no question,” observed a clinical research nurse associated with the trial trials. “But patients consistently report that even when the skin reactions are severe, managing it with topical creams is far preferable to the profound, bone-deep fatigue and intractable nausea that accompanies standard intravenous chemotherapy.”

Importantly, validated patient-reported outcome questionnaires utilized throughout the trial confirmed that daraxonrasib significantly delayed the overall time to symptom deterioration, providing superior pain control and preserving overall global health status scores for longer durations than the control arm.

The Broader Regulatory and Political Landscape

The presentation of the RASolute 302 data occurs amidst intensifying political focus on federal drug approval timelines and the cost of oncology care in the United States. In late 2025, the FDA granted daraxonrasib both Breakthrough Therapy Designation and Orphan Drug Designation, recognizing its potential to fill an absolute therapeutic void. Following the initial top-line survival disclosures by Revolution Medicines in April 2026, the FDA took the rare step on May 1, 2026, of authorizing an official Expanded Access Program (EAP).

The EAP allows pre-screened patients with previously treated metastatic pancreatic cancer to legally access and use daraxonrasib through their local oncologists while the manufacturer completes its final rolling New Drug Application (NDA) submission. This regulatory mechanism acts as a critical safety valve for patients who do not meet the rigid inclusion criteria of ongoing trials but cannot afford to wait for the lengthy formal approval process to conclude.

“This is the first RAS inhibitor evaluated in a large, randomized trial for patients with pancreatic cancer, and it demonstrates how important an impact these novel medicines are likely to have on the treatment of the disease,” Dr. Wolpin noted in an official institutional briefing statement. “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.”

Financially, the impending entry of daraxonrasib into the commercial marketplace is expected to ignite renewed legislative debate over Medicare pricing structures for oral specialty drugs. Because the medication was selected for the FDA Commissioner’s National Priority Voucher pilot program, its regulatory review timeline will be severely compressed. Independent healthcare economists project that if approved by late autumn, the drug will command a premium pricing tier typical of specialized precision oncology, intensifying pressure on private insurers and federal programs to mandate comprehensive coverage without exorbitant out-of-pocket costs for terminal patients.

Concurrently, researchers are already moving to investigate the drug in earlier stages of the disease. A parallel global Phase 3 trial, dubbed RASolute 303, has initiated enrollment to evaluate the efficacy of daraxonrasib as a frontline option, testing it in combination with standard chemotherapy regimens directly at the time of initial metastatic diagnosis. Additionally, laboratory teams are actively sequencing tumor biopsies from patients who eventually progressed on the drug to map out the primary and adaptive mechanisms of resistance, laying the groundwork for future combination regimens that could extend survival boundaries even further.